Oxford Nanopore Technologies plc Oxford Nanopore announces technology updates
02 Dezembro 2021 - 4:00AM
RNS Non-Regulatory
TIDMONT
Oxford Nanopore Technologies plc
02 December 2021
Oxford Nanopore announces technology updates at Nanopore
Community Meeting
Highlights include release of new "Kit 12" and R10.4 flow cells
for >Q20 (>99%) raw read and around Q30 (99.9%) Duplex
sequencing accuracy, and the new PromethION P2 device, a
palm-sized, high-throughput sequencer that delivers the most
accessible low-cost, high-output Oxford Nanopore sequencer
Oxford, UK: Oxford Nanopore has provided a technology update at
its Nanopore Community Meeting, describing a range of product
releases and upgrades. These include the release of "Kit 12", a new
kit that includes the latest "Q20+" chemistry and enables "Duplex"
sequencing. This is coupled with the release of R10.4 flow cells.
Users of nanopore sequencing can now achieve >Q20 raw
read/"simplex" accuracy or around Q30 Duplex accuracy, and
enhanced, high-accuracy consensus sequencing and variant calling,
using these released products.
The Company has also announced PromethION 2 (P2), a device that
can run up to two high-throughput PromethION Flow Cells, which will
be available in starter packs from US$10,455. The P2 is designed to
bring low-cost nanopore sequencing for large genomes or
high-throughput long-read transcriptomics, without the requirement
for capital investment and with minimal infrastructure requirement.
P2 will be available as a standalone device with integrated
compute, or "P2 Solo", a sequencing device that can be connected to
existing compute, including GridION. P2 Solo will be shipped from
Q2 2022 and Oxford Nanopore is now taking pre orders here .
Oxford Nanopore also introduced Remora, a new tool for
methylation analysis. Remora further enhances base-modification
analysis, and is used during the experiment (concurrent to standard
basecalling), at no additional cost, while maintaining
high-accuracy basecalling of native bases. Remora provides
industry-leading performance at only 20X coverage.
"Short fragment mode" (SFM), to optimise accurate,
high-throughput sequencing of shorter fragments as short as 20 bp,
will be fully enabled in the new year. Oxford Nanopore's technology
sequences DNA or RNA molecules of any length, from short to
ultra-long. However, software output settings have historically
avoided shorter "adapter only" reads. SFM is designed to optimise
applications where larger volumes of shorter fragments require
high-accuracy analysis, supporting as many as 250M native human
reads, at 200 bp, on a PromethION flow cell.
"Path to in-field liquid biopsy" . R&D pipeline programmes
were reviewed, including chemistries such as "inny" and "outy",
that capture a single molecule of DNA and make multiple
measurements of that single molecule. These techniques have the
potential to deliver "Adaptive Accuracy" - supporting capture and
re-reading of rare variants in a mixed sample. could be paired with
liquid biopsy workflows in the lab or in the field, potentially
enabling easy-to-use remote "liquid biopsy" sequencing.
The Company is developing an integrated sequencer and tablet;
the MinION Mk1D , that would be capable of processing the high data
volumes produced by MinION and could be used for this purpose.
Nanopore Community Meeting
The annual Nanopore Community Meeting, held online in 2021, has
this year featured more than 50 user talks, spanning areas
including human genetics, clinical / cancer research, microbiology
including genomic epidemiology, plant and animal research and
bioinformatics. Write ups and videos of the talks are made
available on the nanopore website. At the meeting, Oxford Nanopore
provided a technology update, featuring Clive G Brown (CTO) and
talks from James Clarke, Stuart Reid and Rosemary Sinclair
Dokos.
For a complete overview of these and more announcements, please
visit Oxford Nanopore's website at
https://nanoporetech.com/about-us/news/oxford-nanopore-announces-technology-updates-nanopore-community-meeting
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFFFEFFTLLIIL
(END) Dow Jones Newswires
December 02, 2021 02:00 ET (07:00 GMT)
Oxford Nanopore Technolo... (LSE:ONT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Oxford Nanopore Technolo... (LSE:ONT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024